Explore Cerebrolysin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, containing a mixture of low-molecular-weight peptides and amino acids with proposed neurotrophic and neuroprotective activity. It has been studied in stroke, traumatic brain injury, and dementia, typically supplied as a pre-made solution rather than a lyophilized powder. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with Cerebrolysin.
Cerebrolysin is a porcine-brain-derived polypeptide preparation manufactured by EVER Pharma (Austria) by controlled enzymatic breakdown of standardised pig brain protein. It contains a mixture of low-molecular-weight neuropeptides (~85%) and free amino acids (~15%), and has been registered in over 50 countries — primarily in Europe, Asia, and the former Soviet Union — for ischaemic stroke, traumatic brain injury, and dementia. It is not FDA-approved in the United States.
Cerebrolysin is proposed to act as a neurotrophic-factor mimetic, with documented effects on neuronal survival, synaptogenesis, neurogenesis, and immunomodulation in pre-clinical models. The active ingredients are heterogeneous (it is a biological extract, not a defined molecule), and the mechanistic literature attributes activity to the embedded neurotrophic-peptide fragments together with their interaction with endogenous BDNF, GDNF, and NGF signalling.
Cerebrolysin has the largest controlled-trial evidence base of any compound in this tier. Pivotal randomised trials include the CASTA trial in acute ischaemic stroke (n=1070, neutral primary endpoint but pre-specified subgroup benefit in moderate-to-severe stroke), the CARS trials in post-stroke aphasia and rehabilitation, CAPTAIN-I and CAPTAIN-II in traumatic brain injury, and multiple trials in vascular dementia and Alzheimer's disease.
Cerebrolysin has a reported half-life of ~few hours (active fragments), and the dose intervals researchers model most often fall around once daily (course of 10–20 days). The active neuropeptide fragments clear within hours, so it is given as daily courses. The neurological effects are thought to outlast the time it spends in the blood. It is catalogued under Memory Peptides on WPA.
61 Cerebrolysin reconstitution calculations have been logged by the WPA community. The most common dose entered is 10mg (8 calculations). The median dose across all sessions is 12mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 60mg (49 sessions). The most common dosing frequency is 5x/week (1 logged protocols), followed by once weekly (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.